Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PM02734

Known as: Depsipeptide PM02734 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Irvalecelisidepsin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
Elisidepsin (elisidepsin trifluoroacetate, Irvalec®, PM02734) is a new synthetic depsipeptide, a result of the PharmaMar… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
PurposeTo determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2011
2011
PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
PURPOSE PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
PM02734 (elisidepsin) is a novel marine-derived cyclic peptide belonging to the Kahalalide family of compounds currently under… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2009
Review
2009
Cancer treatments: can we find treasures at the bottom of the sea?
Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line… Expand
Is this relevant?
2008
2008
Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
2513 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro… Expand
Is this relevant?
2006
2006
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma.
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a… Expand
Is this relevant?
2006
2006
Activity of pm02734 against human breast and prostate tumors
4712 The novel investigational agent PM02734 is a member of the Kahalalide F family of compounds that display marked anttumor… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE